or Try an Advanced Search...

    Dyslipidemia Stocks List

    Symbol Grade Name % Change
    VKTX B Viking Therapeutics, Inc. -2.98
    ARGX C argenx SE -2.87
    MDGL D Madrigal Pharmaceuticals, Inc. 1.33
    ABT F Abbott Laboratories -0.74
    IONS F Ionis Pharmaceuticals, Inc. -0.82
    View As Page of Charts
    Related Industries: Biotechnology Medical Devices
    Related Stock Lists: Lipid Cancer Diabetes Thyroid Alcohol Biopharmaceutical Cholesterol Hypercholesterolemia Inflammation Medication Medicine Metabolic Disease Obesity Steatohepatitis Acromegaly Acute Myeloid Leukemia Alport Syndrome Amyloid Amyloidosis Anemia

    Related ETFs - A few ETFs which own one or more of the above listed Dyslipidemia stocks.

    Symbol Grade Name Weight
    IHI D iShares U.S. Medical Devices ETF 15.95
    EWK A iShares MSCI Belgium Capped Investable Market Index Fund 6.71
    ULTY C Tidal Trust II YieldMax Ultra Option Income Strategy ETF 5.68
    SURI D Simplify Exchange Traded Funds Simplify Propel Opportunities ETF 5.62
    SBIO D ALPS Medical Breakthroughs ETF 5.37
    View all Dyslipidemia ETFs...
    Compare ETFs
    Compare EWK to SBIO Compare EWK to ULTY Compare SURI to SBIO

        Dyslipidemia Stocks Recent News

        Date Stock Title
        May 17 IONS Ionis, Biogen Down on Ending Development of ALS Drug
        May 17 VKTX 4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
        May 17 ABT Abbott (ABT) Down 0.4% Since Last Earnings Report: Can It Rebound?
        May 17 IONS Ionis (IONS), Biogen Down on Ending Development of ALS Drug
        May 17 MDGL 3 High Insider Ownership US Stocks With Up To 55% Revenue Growth
        May 16 VKTX Viking falls after Roche’s obesity drug data; RayJay upgrades (update)
        May 16 IONS Biogen also drops collaboration with Ionis on Angelman syndrome candidate
        May 16 IONS Biogen and Ionis drop ALS candidate after trial setback
        May 16 IONS Biogen, Ionis shelve ALS drug following study failure
        May 16 ABT These Dividend Stocks Are an Investor's Best Friend
        May 16 IONS REFILE-UPDATE 2-Biogen, Ionis to discontinue development of experimental ALS drug
        May 16 IONS Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
        May 16 IONS Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
        May 16 IONS Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome
        May 16 MDGL John Paulson's Strategic Moves in Q1 2024 Highlight Madrigal Pharmaceuticals' Prominent Role
        May 15 ABT Tudor Investment's top buys and sells in Q1
        May 15 VKTX Here's How Much $1000 Invested In Viking Therapeutics 5 Years Ago Would Be Worth Today
        May 15 VKTX Should You Hold Viking Therapeutics (VKTX) in Your Portfolio?
        May 15 ABT Abbott recalls HeartMate 3 over potential blood leakage, air issues
        May 15 ABT Abbott recalls Heartmate pump after 70 injuries, 2 deaths reported
        Related Industries: Biotechnology Medical Devices
        Related Stock Lists: Lipid Cancer Diabetes Thyroid Alcohol Biopharmaceutical Cholesterol Hypercholesterolemia Inflammation Medication Medicine Metabolic Disease Obesity Steatohepatitis Acromegaly Acute Myeloid Leukemia Alport Syndrome Amyloid Amyloidosis Anemia
        Dyslipidemia

        Dyslipidemia is an abnormal amount of lipids (e.g. triglycerides, cholesterol and/or fat phospholipids) in the blood. In developed countries, most dyslipidemias are hyperlipidemias; that is, an elevation of lipids in the blood. This is often due to diet and lifestyle. Prolonged elevation of insulin levels can also lead to dyslipidemia. Likewise, increased levels of O-GlcNAc transferase (OGT) may cause dyslipidemia.

        More about Dyslipidemia
        Browse All Tags